Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis

Cell Death and Disease

Volumn 4, Issue 6, 2013, Pages

  Ehrhardt, H ^a,b   Wachter, F ^a   Grunert, M ^a   Jeremias, I ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

apoptosis; cell cycle arrest; cyclins; DR5; TRAIL

Indexed keywords

CAFFEINE; CYCLIN B; CYCLIN E; DEXAMETHASONE; METHOTREXATE; MIMOSINE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE SILENCING; HUMAN; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE;

EID: 84879677822     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.179     Document Type: Article

References (39)

1. Li Y, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 2012; 72: 576-580.
2. Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012; 13: e83-e89.
3. Mordant P, Loriot Y, Lahon B, Castier Y, Lesèche G, Soria JC et al. Minimal residual disease in solid neoplasia: new frontier or red-herring? Cancer Treat Rev 2012; 38: 101-110.
4. Mü ller V, Alix-Panabières C, Pantel K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 2010; 46: 1189-1197.
5. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16: 1701-1708.
6. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-798.
7. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008; 118: 1979-1990.
8. Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011; 11: 431-449.
9. Testa U. TRAIL/TRAIL-R in hematologic malignancies. J Cell Biochem 2010; 110: 21-34.
10. Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosisinducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006; 55: 76-84.
11. Ehrhardt H, Wachter F, Maurer M, Stahnke K, Jeremias I. Important role of Caspase-8 for chemo-sensitivity of ALL cells. Clin Cancer Res 2011; 17: 7605-7613.
12. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin-and bortezomib-induced cell death. Br J Haematol 2005; 130: 501-510.
13. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9: 3731-3741.
14. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96: 3900-3906.
15. Brooks CL, Gu W. New insights into p53 activation. Cell Res 2010; 20: 614-621.
16. Resnick-Silverman L, Manfredi JJ. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. J Cell Biochem 2006; 99: 679-689.
17. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID et al. KILLER/DR5 is a DNA damage inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.
18. Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, Graubner U et al. Optimized anti-tumor effects of anthracyclines plus vinca alkaloids using a novel, mechanism-based application schedule. Blood 2011; 118: 6123-6131.
19. Castro Alves C, Terziyska N, GrunertM, Gündisch S, Graubner U, Quintanilla-Martinez L et al. Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood 2012; 119: 4224-4227.
20. Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002; 1: 82-89.
21. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004; 64: 337-346.
22. Ray S, Shyam S, Fraizer GC, Almasan A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther 2007; 6: 1368-1378.
23. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
24. Ehrhardt H, Höfig I, Wachter F, Obexer P, Fulda S, Terziyska N et al. NOXA as critical mediator for drug combinations in polychemotherapy. Cell Death Dis 2012; 3: e327.
25. Ehrhardt H, Pannert L, Pfeiffer S, Amtmann E, Jeremias I. Enhanced anti-tumor effects of vinca alkaloids given separately from cytostatic therapies. Br J Pharmacol 2012; 168: 1558-1569; online first.
26. Anastasov N, Klier M, Koch I, Angermeier D, Hö fler H, Fend F et al. Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J Hematop 2009; 2: 9-19.
27. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008; 22: 2097-2105.
28. Ehrhardt H, Haecker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A et al. Cytotoxic drug-induced, p53-mediated upregulation of Caspase-8 in tumor cells. Oncogene 2008; 27: 783-793.
29. Greshock J, Nathanson K, Martin AM, Zhang L, Coukos G, Weber BL et al. Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Cancer Res 2007; 67: 3594-3600.
30. Sandberg R, Ernberg I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc Natl Acad Sci USA 2005; 102: 2052-2057.
31. Peller S, Rotter V. TP53 in hematologic cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21: 1017-1026.
32. Höfig I, Ehrhardt H, Jeremias I. Efficient RNA interference in patients' acute lymphoblastic leukemia cells amplified as xenografts in mice. Cell Commun Signal 2012; 10: 8.
33. Schmitz M, Breithaupt P, Scheidegger N, Cario G, Bonapace L, Meissner B et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 2011; 118: 1854-1864.
34. Schlereth K, Charles JP, Bretz AC, Stiewe T. Life or death: p53-induced apoptosis requires DNA binding cooperativity. Cell Cycle 2010; 9: 4068-4076.
35. Schlereth K, Beinoraviciute-Keller R, Zeitlinger MK, Bretz AC, Sauer M, Charles JP et al. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 2010; 38: 356-368.
36. Gonzalves F, Ashkenazi A. New insights into apoptosis signalling by Apo2L/TRAIL. Oncogene 2010; 29: 4752-4765.
37. Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res 1975; 35: 2619-2630.
38. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 2007; 13: 7280-7287.
39. Grunert M, Gottschalk K, Kapahnke J, Gündisch S, Kieser A, Jeremias I. The adaptor protein FADD and the initiator Caspase-8 mediate activation of NF-kB by TRAIL. Cell Death Dis 2012; 3: e414.